{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:41:24Z","timestamp":1790628084705,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.autrev.2025.103816","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:41:36Z","timestamp":1744299696000},"page":"103816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases"],"prefix":"10.1016","volume":"24","author":[{"given":"Zahra","family":"Khademi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Mottaghi-Dastjerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Morad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103816_bb0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0010","article-title":"Genome editing using CRISPR-Cas9 and autoimmune diseases: a comprehensive review","volume":"23","author":"Lee","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103816_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0025","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103816_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103816_bb0035","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.autrev.2025.103816_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102764","article-title":"Long-term use of immunosuppressive agents increased the risk of fractures in patients with autoimmune diseases: an 18-year population-based cohort study","volume":"11","author":"Kao","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2025.103816_bb0045","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm.3897","article-title":"Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies","volume":"21","author":"Cho","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12016-014-8451-x","article-title":"Gene therapy for autoimmune disease","volume":"49","author":"Shu","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.pmbts.2021.01.007","article-title":"CRISPR interference and its applications","volume":"180","author":"Ghavami","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2025.103816_bb0065","doi-asserted-by":"crossref","first-page":"125sr1","DOI":"10.1126\/scitranslmed.3003504","article-title":"Treating human autoimmunity: current practice and future prospects","volume":"4","author":"Rosenblum","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/B978-1-4557-0268-8.00097-X","article-title":"Long-term toxicity of immunosuppressive therapy","volume":"1354","author":"Ruiz","year":"2015","journal-title":"Transplant Liver"},{"key":"10.1016\/j.autrev.2025.103816_bb0075","first-page":"283","article-title":"Biologic therapies for autoimmune and connective tissue diseases","volume":"37","author":"Wolfe","year":"2017","journal-title":"Immunol Allergy Clin"},{"key":"10.1016\/j.autrev.2025.103816_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.autrev.2025.103816_bb0085","doi-asserted-by":"crossref","first-page":"e235429","DOI":"10.1001\/jamahealthforum.2023.5429","article-title":"Patient out-of-pocket costs for biologic drugs after biosimilar competition","volume":"5","author":"Feng","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.autrev.2025.103816_bb0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.14430","article-title":"Market share and costs of biologic therapies for inflammatory bowel disease in the USA","volume":"47","author":"Yu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-024-01034-5","article-title":"Current advancements in cellular immunotherapy for autoimmune disease","volume":"47","author":"Berry","year":"2025","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2025.103816_bb0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00281-021-00887-4","article-title":"Functional interrogation of autoimmune disease genetics using CRISPR\/Cas9 technologies and massively parallel reporter assays","volume":"44","author":"Ding","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2025.103816_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcdb.2019.05.007","article-title":"CRISPR\/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases","volume":"96","author":"Singh","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.autrev.2025.103816_bb0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103816_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119691","article-title":"A novel dual-targeting delivery system for specific delivery of CRISPR\/Cas9 using hyaluronic acid, chitosan and AS1411","volume":"292","author":"Khademi","year":"2022","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.autrev.2025.103816_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s42003-020-01340-2","article-title":"A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy","volume":"3","author":"Matsumoto","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.autrev.2025.103816_bb0125","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103816_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5483\/BMBRep.2017.50.1.128","article-title":"CRISPR as a strong gene editing tool","volume":"50","author":"Shen","year":"2017","journal-title":"BMB Rep"},{"key":"10.1016\/j.autrev.2025.103816_bb0135","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2025.103816_bb0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acschembio.7b00657","article-title":"CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine","volume":"13","author":"Kampmann","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.autrev.2025.103816_bb0145","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103816_bb0150","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.3536","article-title":"CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes","volume":"34","author":"Evers","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2025.103816_bb0155","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41593-018-0077-5","article-title":"CRISPR interference-based specific and efficient gene inactivation in the brain","volume":"21","author":"Zheng","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.autrev.2025.103816_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2024.100693","article-title":"Seed sequences mediate off-target activity in the CRISPR-interference system","volume":"4","author":"Rohatgi","year":"2024","journal-title":"Cell Genomics"},{"key":"10.1016\/j.autrev.2025.103816_bb0165","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3390\/genes13112029","article-title":"CRISPR\/Cas9 Genome-editing technology and potential clinical application in gastric cancer","volume":"13","author":"Almeida","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.autrev.2025.103816_bb0170","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.autrev.2025.103816_bb0175","doi-asserted-by":"crossref","first-page":"2408608","DOI":"10.1002\/advs.202408608","article-title":"Programmable macrophage vesicle based bionic self-adjuvanting vaccine for immunization against monkeypox virus","volume":"12","author":"Lin","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110531","article-title":"The developing role of extracellular vesicles in autoimmune diseases: special attention to mesenchymal stem cell-derived extracellular vesicles","volume":"122","author":"Ortiz","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2025.103816_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.749192","article-title":"Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1084\/jem.190.3.385","article-title":"Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis","volume":"190","author":"Rabinovich","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2025.103816_bb0200","article-title":"Function and role of regulatory T cells in rheumatoid arthritis","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0205","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti\u2013citrullinated protein antibody\u2013mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103816_bb0210","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1038\/s41467-020-18180-7","article-title":"Analysis of chromatin organization and gene expression in T cells identifies functional genes for rheumatoid arthritis","volume":"11","author":"Yang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103816_bb0215","doi-asserted-by":"crossref","first-page":"8883","DOI":"10.3390\/ijms22168883","article-title":"Modulation of PTPN2\/22 function by spermidine in CRISPR-Cas9-edited T-cells associated with Crohn\u2019s disease and rheumatoid arthritis","volume":"22","author":"Shaw","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/326042","article-title":"CRISPR\/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264. 7 cells","volume":"2015","author":"Jing","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2025.103816_bb0225","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2025.103816_bb0230","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3748\/wjg.v25.i18.2177","article-title":"Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease","volume":"25","author":"Limanskiy","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103816_bb0235","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"de Lange","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0240","article-title":"Olanzapine-induced lipid disturbances: a potential mechanism through the gut microbiota-brain axis","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103816_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156402","article-title":"Gut microbiota as a new target for hyperuricemia: a perspective from natural plant products","volume":"138","author":"Dong","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.autrev.2025.103816_bb0250","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1039\/D3FO04858F","article-title":"Intestinal toxicity alleviation and efficacy potentiation through therapeutic administration of Lactobacillus paracasei GY-1 in the treatment of gout flares with colchicine","volume":"15","author":"Zeng","year":"2024","journal-title":"Food Funct"},{"key":"10.1016\/j.autrev.2025.103816_bb0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0260","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2017.88","article-title":"Gut microbiota and IBD: causation or correlation?","volume":"14","author":"Ni","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103816_bb0265","doi-asserted-by":"crossref","first-page":"1700583","DOI":"10.1002\/biot.201700583","article-title":"Genome editing with CRISPR-Cas9 in Lactobacillus plantarum revealed that editing outcomes can vary across strains and between methods","volume":"14","author":"Leenay","year":"2019","journal-title":"Biotechnol J"},{"key":"10.1016\/j.autrev.2025.103816_bb0270","doi-asserted-by":"crossref","first-page":"20180103","DOI":"10.1098\/rstb.2018.0103","article-title":"Editing the microbiome the CRISPR way","volume":"374","author":"Ramachandran","year":"2019","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0275","series-title":"Streamlined, recombinase-free genome editing with CRISPR-Cas9 in Lactobacillus plantarum reveals barriers to efficient editing","first-page":"352039","author":"Leenay","year":"2018"},{"key":"10.1016\/j.autrev.2025.103816_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-042320-021020","article-title":"The gut microbiome and inflammatory bowel diseases","volume":"73","author":"Shan","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0285","article-title":"Recent advances in host-focused molecular tools for investigating host-gut microbiome interactions","volume":"15","author":"Wang","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.autrev.2025.103816_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2025.103816_bb0295","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1038\/ncomms11627","article-title":"T-bet is a key modulator of IL-23-driven pathogenic CD4+ T cell responses in the intestine","volume":"7","author":"Krausgruber","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103816_bb0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2018.02.001","article-title":"Epigenetic editing: How cutting-edge targeted epigenetic modification might provide novel avenues for autoimmune disease therapy","volume":"196","author":"Jeffries","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.pmbts.2020.12.002","article-title":"CRISPR\/dCas system as the modulator of gene expression","volume":"178","author":"Kazi","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0310","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1093\/nar\/gkt520","article-title":"Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system","volume":"41","author":"Bikard","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2025.103816_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212850","article-title":"The Crohn\u2019s disease associated SNP rs6651252 impacts MYC gene expression in human colonic epithelial cells","volume":"14","author":"Matthews","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103816_bb0320","doi-asserted-by":"crossref","first-page":"14865","DOI":"10.3390\/ijms241914865","article-title":"CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation","volume":"24","author":"Cai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0325","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1053\/j.gastro.2015.08.001","article-title":"Genetics of inflammatory bowel diseases","volume":"149","author":"McGovern","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103816_bb0330","first-page":"308","article-title":"A personalized approach to managing inflammatory bowel disease","volume":"12","author":"Kingsley","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103816_bb0335","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17745029","article-title":"Inflammatory bowel disease: towards a personalized medicine","volume":"11","author":"Flamant","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103816_bb0340","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1039\/D0BM01359E","article-title":"Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease","volume":"9","author":"Verma","year":"2021","journal-title":"Biomater Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0345","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/ng.3947","article-title":"A functional genomics predictive network model identifies regulators of inflammatory bowel disease","volume":"49","author":"Peters","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0350","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cell.2015.06.059","article-title":"A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks","volume":"162","author":"Parnas","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103816_bb0355","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1093\/hmg\/ddaa097","article-title":"Functional genomics in autoimmune diseases","volume":"29","author":"Ding","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0360","doi-asserted-by":"crossref","first-page":"ftz060","DOI":"10.1093\/femspd\/ftz060","article-title":"Next-generation technologies for studying host\u2013pathogen interactions: a focus on dual transcriptomics, CRISPR\/Cas9 screening and organs-on-chips","volume":"77","author":"Baddal","year":"2019","journal-title":"Pathog Dis"},{"key":"10.1016\/j.autrev.2025.103816_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e35836","article-title":"Advancements and challenges in stem cell transplantation for regenerative medicine","volume":"10","author":"Wei","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2025.103816_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155354","article-title":"Cause and consequence of heterogeneity in human mesenchymal stem cells: challenges in clinical application","volume":"260","author":"Lyu","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.autrev.2025.103816_bb0375","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","article-title":"Advances in stem cell research and therapeutic development","volume":"21","author":"De Luca","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.autrev.2025.103816_bb0380","first-page":"48","article-title":"TGF-beta1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients","volume":"11","author":"Zhuo","year":"2024","journal-title":"Mil Med Res"},{"key":"10.1016\/j.autrev.2025.103816_bb0385","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/stmcls\/sxac014","article-title":"Molecular manipulations and intestinal stem cell-derived organoids in inflammatory bowel disease","volume":"40","author":"Boye","year":"2022","journal-title":"Stem Cells"},{"key":"10.1016\/j.autrev.2025.103816_bb0390","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2147\/JIR.S400447","article-title":"Stem cell therapy in inflammatory bowel disease: a review of achievements and challenges","author":"Tian","year":"2023","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.autrev.2025.103816_bb0395","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/1040841X.2021.1876631","article-title":"Inflammatory bowel disease: tri-directional relationship between microbiota, immune system and intestinal epithelium","volume":"47","author":"Ahlawat","year":"2021","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.autrev.2025.103816_bb0400","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.chom.2022.12.004","article-title":"Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice","volume":"31","author":"Zou","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.autrev.2025.103816_bb0405","doi-asserted-by":"crossref","first-page":"25657","DOI":"10.1021\/acsnano.4c07750","article-title":"Oral microto-nano genome-editing system enabling targeted delivery and conditional activation of CRISPR-Cas9 for gene therapy of inflammatory bowel disease","volume":"18","author":"Lin","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.autrev.2025.103816_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010301","article-title":"Up-regulated expression of pro-apoptotic long noncoding RNA lincRNA-p21 with enhanced cell apoptosis in lupus nephritis","volume":"22","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0415","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/art.42390","article-title":"Integrative functional genomics identifies systemic lupus erythematosus causal genetic variant in the IRF5 risk locus","volume":"75","author":"Hou","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103816_bb0420","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103816_bb0425","series-title":"A multilayered post-GWAS analysis pipeline defines functional variants and target genes for systemic lupus erythematosus (SLE), medRxiv","author":"Fazel-Najafabadi","year":"2023"},{"key":"10.1016\/j.autrev.2025.103816_bb0430","article-title":"NK cells in autoimmune diseases: protective or pathogenic?","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0435","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein\u2013Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1586\/14737175.2013.865866","article-title":"Environmental factors in multiple sclerosis","volume":"13","author":"Ascherio","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.autrev.2025.103816_bb0445","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0450","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2022.12.020","article-title":"Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis","volume":"109","author":"Schepers","year":"2023","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.autrev.2025.103816_bb0460","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ng2103","article-title":"Interleukin 7 receptor \u03b1 chain (IL7R) shows allelic and functional association with multiple sclerosis","volume":"39","author":"Gregory","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000322","article-title":"IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production","volume":"5","author":"Maier","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0470","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cell.2017.03.007","article-title":"Human epistatic interaction controls IL7R splicing and increases multiple sclerosis risk","volume":"169","author":"Galarza-Mu\u00f1oz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103816_bb0475","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103816_bb0480","series-title":"The forefront of a revolution: The applications of CRISPR-Cas9 technology to treat multiple sclerosis","author":"Malkani","year":"2022"},{"key":"10.1016\/j.autrev.2025.103816_bb0485","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymthe.2017.09.001","article-title":"Gene therapy-induced antigen-specific Tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis","volume":"26","author":"Keeler","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0490","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13287-017-0511-8","article-title":"CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?","volume":"8","author":"Gerace","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0495","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"A.D. Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2025.103816_bb0500","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.autrev.2025.103816_bb0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","article-title":"CRISPR-Cas9 applications in T cells and adoptive T cell therapies","volume":"29","author":"Chen","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.autrev.2025.103816_bb0510","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.4049\/jimmunol.1700024","article-title":"Genetic and small molecule disruption of the AID\/RAD51 axis similarly protects nonobese diabetic mice from type 1 diabetes through expansion of regulatory B lymphocytes","volume":"198","author":"Ratiu","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010344","article-title":"Applications of genome-editing technologies for type 1 diabetes","volume":"25","author":"El Nahas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0520","doi-asserted-by":"crossref","first-page":"1142648","DOI":"10.3389\/fimmu.2023.1142648","article-title":"Modeling cell-mediated immunity in human type 1 diabetes by engineering autoreactive CD8(+) T cells","volume":"14","author":"Peters","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0525","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/db17-1467","article-title":"Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development","volume":"67","author":"Racine","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2025.103816_bb0530","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.2337\/db16-0061","article-title":"CRISPR-Cas9\u2013mediated modification of the NOD mouse genome with Ptpn22R619W mutation increases autoimmune diabetes","volume":"65","author":"Lin","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2025.103816_bb0535","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.autrev.2025.103816_bb0540","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrd4231","article-title":"Targeting the pancreatic \u03b2-cell to treat diabetes","volume":"13","author":"Vetere","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2025.103816_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-017-0694-z","article-title":"PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration","volume":"8","author":"Zhu","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0550","doi-asserted-by":"crossref","first-page":"17472","DOI":"10.1038\/s41598-017-17805-0","article-title":"CRISPR\/Cas9 microinjection in oocytes disables pancreas development in sheep","volume":"7","author":"Vilarino","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103816_bb0555","first-page":"104","article-title":"Current approaches in regenerative medicine for the treatment of diabetes: introducing CRISPR\/CAS9 technology and the case for non-embryonic stem cell therapy","volume":"7","author":"Coombe","year":"2018","journal-title":"Am J Stem Cells"},{"key":"10.1016\/j.autrev.2025.103816_bb0560","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s42255-020-0254-1","article-title":"Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes","volume":"2","author":"Cai","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.autrev.2025.103816_bb0565","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.abh1657","article-title":"Strategies for durable \u03b2 cell replacement in type 1 diabetes","volume":"373","author":"Brusko","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103816_bb0570","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2020.1748596","article-title":"Cell therapy for type 1 diabetes","volume":"20","author":"Loretelli","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0575","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15240","article-title":"Application of CRISPR-Cas9 technology in diabetes research","volume":"41","author":"Lotfi","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0580","article-title":"Editorial: Genome editing applications of CRISPR\/Cas9 in metabolic diseases, hormonal system and cancer research","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.autrev.2025.103816_bb0585","series-title":"Book using modern genome editing technology, specifically CRISPR-Cas9, to determine genes associated with the increased risk of rheumatic disease","article-title":"Using modern genome editing technology, specifically CRISPR-Cas9, to determine genes associated with the increased risk of rheumatic disease","author":"Gough","year":"2021"},{"key":"10.1016\/j.autrev.2025.103816_bb0590","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40291-023-00642-5","article-title":"A review of CRISPR-based advances in dermatological diseases","volume":"27","author":"Lu","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0595","article-title":"A review on epigenome editing using CRISPR-based tools to rejuvenate skin tissues","volume":"2","author":"Sichani","year":"2023","journal-title":"Int J Bioinform Intell Comput"},{"key":"10.1016\/j.autrev.2025.103816_bb0600","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1101\/gr.251561.119","article-title":"A genome-wide long noncoding RNA CRISPRi screen identifies PRANCR as a novel regulator of epidermal homeostasis","volume":"30","author":"Cai","year":"2020","journal-title":"Genome Res"},{"key":"10.1016\/j.autrev.2025.103816_bb0605","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tig.2023.01.002","article-title":"iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies","volume":"39","author":"Palasantzas","year":"2023","journal-title":"Trends Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0610","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.tips.2023.09.006","article-title":"Celiac disease: mechanisms and emerging therapeutics","volume":"44","author":"Besser","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2025.103816_bb0615","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MEG.0000000000002480","article-title":"DQA1*0102 DQB1*0602 haplotype distinguishes coeliac disease and its complications from gluten unrelated enteropathies","volume":"35","author":"De Silvestri","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103816_bb0620","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/imr.12191","article-title":"IL-15: a central regulator of celiac disease immunopathology","volume":"260","author":"Abadie","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2025.103816_bb0625","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2020.575844","article-title":"Beyond the HLA genes in gluten-related disorders","volume":"7","author":"Sallese","year":"2020","journal-title":"Front Nutr"},{"key":"10.1016\/j.autrev.2025.103816_bb0630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aad0467","article-title":"A long noncoding RNA associated with susceptibility to celiac disease","volume":"352","author":"Castellanos-Rubio","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103816_bb0635","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.20231490","article-title":"Autoimmunity-related LINC01934 and AP002954.4 lncRNA polymorphisms may be effective in pediatric celiac disease: a case-control study","volume":"70","author":"Orenay-Boyacioglu","year":"2024","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.autrev.2025.103816_bb0640","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gutjnl-2014-306931","article-title":"The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease","volume":"64","author":"Olivares","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2025.103816_bb0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249861","article-title":"Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection","volume":"16","author":"Bj\u00f6rkqvist","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2025.103816_bb0650","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/1744666X.2021.1840354","article-title":"Gut microbiota in Celiac Disease: microbes, metabolites, pathways and therapeutics","volume":"16","author":"Olshan","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0655","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103816_bb0660","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/iub.2296","article-title":"CRISPR\/Cas9 gene editing: a new therapeutic approach in the treatment of infection and autoimmunity","volume":"72","author":"Mohammadzadeh","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.autrev.2025.103816_bb0665","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.208.Supp.56.17","article-title":"CRISPRi and KO screens reveal integrated cis- and trans-regulation of the CD28, CTLA4, and ICOS locus in primary human T cells","volume":"208","author":"Mowery","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103816_bb0670","article-title":"Application and perspective of CRISPR\/Cas9 genome editing technology in human diseases modeling and gene therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Genet"},{"key":"10.1016\/j.autrev.2025.103816_bb0675","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0680","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2025.103816_bb0685","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-021-01487-4","article-title":"Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy","volume":"21","author":"Rasul","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.autrev.2025.103816_bb0690","first-page":"179","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics, Precis","volume":"4","author":"Liu","year":"2021","journal-title":"Clin Med"},{"key":"10.1016\/j.autrev.2025.103816_bb0695","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/crispr.2024.0042","article-title":"Affordable pricing of CRISPR treatments is a pressing ethical imperative","volume":"7","author":"Rueda","year":"2024","journal-title":"Crispr J"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722500076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722500076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:06:47Z","timestamp":1749323207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722500076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":139,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S156899722500076X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103816","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103816"}}